|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HER2 positivity, ENE, PNI and mSLN diameter ≥10,5 mm were found to be very strong predictors in nonSLN metastasis development.
|
31519397 |
2020 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the adjusted analysis, a positive SN was associated with younger age (P = 0.0001) and a positive human epidermal growth factor 2 receptor (HER2) status (P = 0.03).
|
30877405 |
2019 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discordant results (all false negatives) were significantly more likely in neoadjuvant therapy patients with Estrogen Receptor-positive/HER2-negative status, and in sentinel lymph node with pN1mic and pN0i+ deposits; age, preneoadjuvant therapy lymph node status, histotype, nuclear grade, tumor size, and response to neoadjuvant therapy showed no significant differences.
|
30803394 |
2019 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, luminal B (OR = 3.311, 95% CI 1.593-6.884; P = 0.001) and HER2 overexpression (OR = 4.308, 95% CI 1.097-16.912; P = 0.036) were independent and statistically significant predictor of non-sentinel lymph node metastasis versus luminal A.
|
29696563 |
2018 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), and Ki-67 in pure DCIS (164 cases), and DCIS with microinvasion (55 cases) using immunohistochemistry.DCIS with microinvasion had a higher nuclear grade (P < .001) and was more likely to have sentinel lymph node biopsy (SLNB) positivity (P = .039) than DCIS.
|
30383678 |
2018 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
In cN1-3 patients, pN0 rates after NAC were 61.3% in ER-/HER2+, 47.7% in ER+/HER2+, 47.3% in ER-/HER2-, and 20.2% in ER+/HER2- and SLN surgery was highest in ER-/HER2+ (28.9%, p < 0.05 versus other subtypes).
|
29181679 |
2018 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer.
|
28838210 |
2017 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients who achieved pCR had an anti-HER2 CD4 immune response in the sentinel lymph node, and the quantified response was higher by response repertoire (<i>P</i> = 0.03) and cumulative response (<i>P</i> = 0.04).<b>Conclusions:</b> Anti-HER2 DC1 vaccination is a safe and immunogenic treatment to induce tumor-specific T-cell responses in HER2<sup>pos</sup> patients; immune and clinical responses were similar independent of vaccination route.
|
27965306 |
2017 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.
|
28241044 |
2017 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression level of HER-2 was positively related to the SLN metastasis (<i>r</i>=0.548).
|
28667103 |
2017 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with core biopsy proven non-lobular invasive breast cancer, (estrogen receptor positive, Her2 negative, maximum tumor size 3.0 cm on diagnostic MRI) and a negative sentinel node biopsy are eligible.
|
28274211 |
2017 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Six candidates (all ER/PR+, HER2-, Ki-67 <20%) with metastatic SLNs selected from 305 patients were equally categorized as NSLN negative and positive.
|
26311227 |
2015 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
The multivariate logistic regression analysis showed that TTL is an independent predictor of metastatic non-SLNs, after adjusting for the tumor size, HER2 status, LVI and, in particular, the number of affected SLNs.
|
23576079 |
2013 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Concordance between BP1 and HER2/NEU copy numbers was found in 68% of the PBT and 90% of the SLN metastasis.
|
18992636 |
2008 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HER-2/neu predicts the presence of SLN micro-metastasis as detected by H&E (P=0.005) and COX-2 overexpression predicts the presence of micro-metastasis in BM (P=0.005) and SLN by H&E (P<0.001) and IHC (P<0.001).
|
16596190 |
2006 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Her-2/neu expression in primary breast cancer with sentinel lymph node metastasis.
|
16408141 |
2006 |